European League Against Rheumatism Archives

Tag: European League Against Rheumatism

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […] Read More

LRA Congratulates AstraZeneca on Positive Data on Anifrolumab Presented at Major Medical Meeting

June 3, 2020 The Lupus Research Alliance (LRA) is encouraged by positive data from two studies presented at the European League Against Rheumatism (EULAR) virtual annual congress on the use of the investigational medication anifrolumab as a potential treatment for people with lupus. Anifrolumab is a novel drug that works by blocking a group of […] Read More

Possible Cancer Drug 2DG May Boost Good Immune Cells

June 20, 2019 The investigational drug 2DG, tested as a cancer treatment, shows promise for lupus in new results reported by researchers from Japan at the European League Against Rheumatism (EULAR) 2019 annual meeting. Previous research had shown that the a potential drug, 2DG, increases the numbers of regulatory T cells, which turn down the […] Read More

New Guidelines for Lupus Treatment From EULAR

April 10, 2019 New recommendations for treating systemic lupus erythematosus were just issued by EULAR – the European League Against Rheumatism (EULAR) and published in Annals of the Rheumatic Diseases . A group of researchers from 29 medical centers across Europe reviewed all the current literature on lupus treatment to formulate questions, elicit expert opinions […] Read More